STRATA Skin Sciences to Participate in the Benchmark Healthcare House Call Virtual 1x1 Investor Conference
2024年5月14日 - 5:30AM
STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ:
SSKN), a medical technology company dedicated to developing,
commercializing, and marketing innovative products for the
treatment of dermatologic conditions, announces that Dr. Dolev
Rafaeli, President and Chief Executive Officer, and Christopher
Lesovitz, Chief Financial Officer, will participate in the
Benchmark Healthcare House Call Virtual 1x1 Investor Conference
being held on May 21 – 22, 2024.
To register, please visit the event page on
Benchmark’s website:
https://www.benchmarkcompany.com/4th-annual-healthcare-house-call-conference/
Dr. Rafaeli and Mr. Lesovitz will be available
for one-on-one meetings on both days of the conference. Investors
can also contact IR@strataskin.com to arrange a meeting.
About STRATA Skin Sciences,
Inc.STRATA Skin Sciences is a medical technology company
dedicated to developing, commercializing and marketing innovative
products for the in-office treatment of various dermatologic
conditions such as psoriasis, vitiligo, and acne. Its products
include the XTRAC® excimer laser, VTRAC® lamp systems,
and the TheraClear®X Acne Therapy System. STRATA is proud to offer
these exciting technologies in the U.S. through its unique
Partnership Program. STRATA’s popular partnership approach includes
a fee per treatment cost structure versus an equipment purchase,
installation and use of the device, on-site training for practice
personnel, service and maintenance of the equipment, dedicated
account and customer service associates, and co-op advertising
support to help raise awareness and promote the program within the
practice.
Safe HarborThis press release
includes "forward-looking statements" within the meaning of the
Securities Litigation Reform Act of 1995. These statements include
but are not limited to the Company’s plans, objectives,
expectations and intentions and may contain words such as “will,”
“may,” “seeks,” and “expects,” that suggest future events or
trends. These statements, the Company’s ability to launch and sell
an acne treatment device and to integrate that device into its
product offerings, the Company’s ability to develop, launch and
sell products recently acquired or to be developed in the future,
the Company’s ability to develop social media marketing campaigns,
direct to dermatologist marketing campaigns, and the Company’s
ability to build a leading franchise in dermatology and aesthetics,
are based on the Company’s current expectations and are inherently
subject to significant uncertainties and changes in circumstances.
Actual results may differ materially from the Company’s
expectations due to financial, economic, business, competitive,
market, regulatory, adverse market conditions labor supply
shortages, or supply chain interruptions resulting from fiscal,
political factors, international conflicts, responses, or
conditions affecting the Company, the medical device industry and
our customers and patients in general, as well as more specific
risks and uncertainties set forth in the Company’s SEC reports on
Forms 10-Q and 10-K. Given such uncertainties, any or all these
forward-looking statements may prove to be incorrect or unreliable.
The statements in this press release are made as of the date of
this press release, even if subsequently made available by the
Company on its website or otherwise. The Company does not undertake
any obligation to update or revise these statements to reflect
events or circumstances occurring after the date of this press
release. The Company urges investors to carefully review its SEC
disclosures available
at www.sec.gov and www.strataskinsciences.com.
Investor Contact:CORE
IR516-222-2560ir@strataskin.com
Strata Skin Sciences (NASDAQ:SSKN)
過去 株価チャート
から 4 2024 まで 5 2024
Strata Skin Sciences (NASDAQ:SSKN)
過去 株価チャート
から 5 2023 まで 5 2024